Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx To Initiates Phase 2 Clinical Trial With Bafetinib
Reportedly, in the planned phase 2 trial, approximately 20 patients who have failed treatment with first-line agents will be administered daily oral doses of Bafetinib. In the study,
Reportedly, in the planned phase 2 trial, approximately 20 patients who have failed treatment with first-line agents will be administered daily oral doses of Bafetinib. In the study,
Taliglucerase alfa is the company’s proprietary plant cell expressed recombinant form of glucocerebrosidase for the treatment of Gaucher disease. The FDA has granted orphan drug designation and fast
Franz Groiss, in-charge of managing clinical studies at Avir, said: “In double blind studies, neither the administering physician (and/or the commissioning party) nor the volunteers know who gets
As per the agreement, TTI is expected to receive an upfront payment. Moreover, it is eligible to receive milestone payments based on achievements of specified clinical, regulatory and
Jean-Jacques Bienaime, chief executive officer of BioMarin, said: “BMN 195 has been shown to upregulate utrophin levels in human muscle cells, as a means of augmenting muscle function.
Through network biology analysis, Sage will use the genetic, molecular and clinical information to create predictive computational disease models. These models will help identify therapeutic targets for oncology
The first antibody conjugate is Nimotuzumab coupled to a radionuclide, indium-111, and a cell-nucleus delivery system developed in the laboratory of Dr. Raymond Reilly, Professor, Leslie Dan Faculty
Following two phase 2a studies that were conducted by Topigen with TPI 1020 in patients with asthma and COPD, NicOx and Topigen had recently been in active discussions
ACH-1625 is an inhibitor of HCV NS3 protease that was discovered and is being developed by Achillion. HCV-infected subjects in the second dosing cohort (n=9, randomized to 6
Novartis also receives certain option rights in cardiovascular and oncology product applications, and rights to use Proteus technologies in its clinical development of pharmaceutical products. Under the terms